BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · IEX Real-Time Price · USD
14.64
+0.27 (1.88%)
At close: Aug 12, 2022 4:00 PM
14.71
+0.07 (0.48%)
After-hours:
Aug 12, 2022 7:57 PM EDT
Income Statement (Annual)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 - 1994 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
|
157.17 | 17.81 | 48.84 | 20.65 | 25.19 | 26.35 | 48.26 | 13.61 | 17.33 | 26.29 | Upgrade
|
| Revenue Growth (YoY)
|
782.38% | -63.53% | 136.45% | -18.00% | -4.43% | -45.39% | 254.62% | -21.48% | -34.09% | 33.85% | Upgrade
|
| Cost of Revenue
|
7.26 | 1.68 | 4.1 | 0.47 | 1.7 | 2.7 | 1.9 | 0.12 | 0.1 | 0.13 | Upgrade
|
| Gross Profit
|
149.91 | 16.14 | 44.73 | 20.18 | 23.48 | 23.65 | 46.36 | 13.49 | 17.23 | 26.16 | Upgrade
|
| Selling, General & Admin
|
118.82 | 67.93 | 37.12 | 29.51 | 13.93 | 11.25 | 13.05 | 7.46 | 6.01 | 9.13 | Upgrade
|
| Research & Development
|
208.81 | 122.96 | 107.07 | 84.89 | 66.96 | 61.01 | 72.76 | 51.8 | 41.94 | 49.16 | Upgrade
|
| Other Operating Expenses
|
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.76 | Upgrade
|
| Operating Expenses
|
327.63 | 190.89 | 144.19 | 114.4 | 80.9 | 72.26 | 85.81 | 59.26 | 47.95 | 60.05 | Upgrade
|
| Operating Income
|
-177.72 | -174.76 | -99.46 | -94.22 | -57.41 | -48.61 | -39.44 | -45.77 | -30.72 | -33.89 | Upgrade
|
| Interest Expense / Income
|
59.29 | 14.5 | 11.89 | 9.18 | 8.57 | 6.49 | 5.2 | 5 | 4.78 | 4.67 | Upgrade
|
| Other Expense / Income
|
-55.21 | -6.44 | -2.45 | -2.14 | -0.19 | 0.05 | -1.63 | -5.58 | -5.39 | 0.53 | Upgrade
|
| Pretax Income
|
-181.81 | -182.81 | -108.9 | -101.25 | -65.78 | -55.14 | -43.02 | -45.19 | -30.11 | -39.08 | Upgrade
|
| Income Tax
|
2.25 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Net Income
|
-184.06 | -182.81 | -108.9 | -101.25 | -65.78 | -55.14 | -43.02 | -45.19 | -30.11 | -39.08 | Upgrade
|
| Net Income Common
|
-184.06 | -182.81 | -108.9 | -101.25 | -65.78 | -55.14 | -43.02 | -45.19 | -30.11 | -39.08 | Upgrade
|
| Shares Outstanding (Basic)
|
179 | 167 | 116 | 103 | 84 | 74 | 73 | 67 | 55 | 49 | Upgrade
|
| Shares Outstanding (Diluted)
|
179 | 167 | 116 | 103 | 84 | 74 | 73 | 67 | 55 | 49 | Upgrade
|
| Shares Change
|
7.08% | 44.70% | 12.03% | 22.18% | 14.59% | 1.09% | 9.18% | 20.93% | 11.61% | 9.59% | Upgrade
|
| EPS (Basic)
|
-1.03 | -1.09 | -0.94 | -0.98 | -0.78 | -0.75 | -0.59 | -0.68 | -0.55 | -0.79 | Upgrade
|
| EPS (Diluted)
|
-1.03 | -1.09 | -0.94 | -0.98 | -0.78 | -0.75 | -0.59 | -0.68 | -0.55 | -0.79 | Upgrade
|
| Free Cash Flow Per Share
|
-0.81 | -0.81 | -0.78 | -0.90 | -0.49 | -0.80 | -0.25 | -0.58 | -0.48 | -0.76 | Upgrade
|
| Gross Margin
|
95.40% | 90.60% | 91.60% | 97.70% | 93.20% | 89.80% | 96.10% | 99.10% | 99.40% | 99.50% | Upgrade
|
| Operating Margin
|
-113.10% | -981.10% | -203.70% | -456.20% | -227.90% | -184.40% | -81.70% | -336.40% | -177.20% | -128.90% | Upgrade
|
| Profit Margin
|
-117.10% | -1026.40% | -223.00% | -490.30% | -261.20% | -209.30% | -89.10% | -332.10% | -173.70% | -148.60% | Upgrade
|
| Free Cash Flow Margin
|
-92.00% | -761.40% | -184.10% | -450.00% | -164.60% | -222.80% | -37.80% | -284.10% | -153.00% | -142.70% | Upgrade
|
| Effective Tax Rate
|
-1.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | Upgrade
|
| EBITDA
|
-121.74 | -167.57 | -96.28 | -91.31 | -56.51 | -48.17 | -37.64 | -40.01 | -25.03 | -33.79 | Upgrade
|
| EBITDA Margin
|
-77.50% | -940.70% | -197.20% | -442.10% | -224.40% | -182.80% | -78.00% | -294.00% | -144.40% | -128.50% | Upgrade
|
| Depreciation & Amortization
|
0.78 | 0.75 | 0.72 | 0.77 | 0.7 | 0.48 | 0.18 | 0.18 | 0.3 | 0.63 | Upgrade
|
| EBIT
|
-122.52 | -168.31 | -97.01 | -92.08 | -57.22 | -48.66 | -37.82 | -40.19 | -25.33 | -34.42 | Upgrade
|
| EBIT Margin
|
-78.00% | -944.90% | -198.60% | -445.80% | -227.20% | -184.60% | -78.40% | -295.30% | -146.20% | -130.90% | Upgrade
|
Source: Financials are provided by
Nasdaq Data Link
and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).